Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra (fo ...
As a result digital systems such as All Source Analysis System-Remote Work Station (ASAS-RWS), All Source Analysis System-Light (ASAS-L), Maneuver Control System( MCS), Joint Early Warning System ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback